Seretide Settlement Lifts Glenmark In Europe
As Indian Firm Shelves Divestment Plans For API Business
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
